GMP IPO Watch
Bajaj Finserv Healthcare Fund
Direct Plan · IDCW · Bajaj Finserv Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.48% | +3.52% | 174 of 255 |
| 1M | +3.19% | +1.97% | 78 of 255 |
| 3M | +2.73% | -3.45% | 14 of 252 |
| 6M | +18.53% | +2.92% | 5 of 251 |
| YTD | +23.59% | +1.21% | 9 of 255 |
| 1Y | +20.06% | +1.11% | 15 of 232 |
| INCEPTION | +10.44% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +4.57% | +22.42% | -13.58% | 68% | 27% |
| 6M | +8.67% | +34.62% | -8.78% | 76% | 32% |
| 1Y | +11.93% | +27.12% | -4.21% | 89% | 39% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity95.56%
- Debt1.31%
- Cash3.13%
- Other0.00%
Market Cap Split
- Large Cap30.33%
- Mid Cap28.79%
- Small Cap36.44%
- Others4.44%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 43.84 | 41.75 |
| P/B | 6.15 | 6.19 |
| Price / Sales | 5.86 | 5.96 |
| Price / Cash Flow | 31.55 | 30.98 |
| Dividend Yield (%) | 0.48 | 0.61 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Divis Laboratories | Pharmaceuticals & Biotechnology | 9.75% | -0.80% |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 8.96% | +0.75% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 6.36% | -0.36% |
| Rubicon Research | Pharmaceuticals & Biotechnology | 6.08% | -0.73% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 6.03% | -0.15% |
| Apollo Hospitals | Equity | 5.51% | -0.49% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 4.78% | -0.25% |
| Emcure Pharmaceuticals | Pharmaceuticals & Biotechnology | 4.03% | +0.19% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 3.91% | +1.55% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 3.82% | -0.29% |
| Max Healthcare Institute | Equity | 2.99% | -0.36% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 2.96% | — |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.57% | +0.01% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.40% | -0.06% |
| Clearing Corporation of India Ltd | Net Current Assets | 2.32% | — |
View all 36 holdings
| Fortis Healthcare | Equity | 2.28% | -0.41% |
| Zydus Wellness | Food Products | 2.20% | -0.07% |
| Vijaya Diagnostic Centre | Equity | 2.19% | -0.12% |
| Senores Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.08% | -0.07% |
| Shaily Engineering Plastics | Consumer Durables | 1.88% | -0.12% |
| Dr. Lal Path Labs | Equity | 1.73% | +0.05% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 1.63% | -0.16% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 1.60% | -0.10% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 1.37% | +0.09% |
| Cipla | Pharmaceuticals & Biotechnology | 1.33% | -0.06% |
| Bajaj Finserv Money Market Fund-Direct Plan-Growth | Money Market | 1.31% | +0.01% |
| Sanofi Consumer Healthcare | Pharmaceuticals & Biotechnology | 1.30% | -0.11% |
| Biocon | Pharmaceuticals & Biotechnology | 1.05% | -0.11% |
| Navin Fluorine International | Chemicals & Petrochemicals | 0.94% | -0.05% |
| Krishna Institute of Medical Sciences | Equity | 0.92% | -0.01% |
| Jubilant Pharmova | Pharmaceuticals & Biotechnology | 0.89% | +0.13% |
| Onesource Specialty Pharma | Pharmaceuticals & Biotechnology | 0.83% | +0.01% |
| Net Receivables / (Payables) | Net Current Assets | 0.81% | — |
| Medi Assist Healthcare | Insurance | 0.75% | -0.07% |
| Neogen Chemicals | Chemicals & Petrochemicals | 0.23% | +0.02% |
| Sumitomo Chemical | Fertilizers & Agrochemicals | 0.21% | -0.04% |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.28 | 16.32 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.86 | -0.32 | Above Average |
| 3Y | 0.29 | -0.45 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.19 | 0.19 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.01 | 0.96 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From Bajaj Finserv Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Bajaj Finserv Small Cap Fund
Direct Plan · Growth
|
+9.98% | — | — | +7.34% |
|
Bajaj Finserv Arbitrage Fund
Direct Plan · IDCW
|
+6.57% | +6.97% | — | +7.01% |
|
Bajaj Finserv Liquid Fund
Direct Plan · Growth
|
+6.50% | +6.92% | — | +6.93% |
|
Bajaj Finserv Money Market Fund
Direct Plan · IDCW
|
+6.36% | +7.29% | — | +7.38% |
|
Bajaj Finserv Multi Cap Fund
Direct Plan · Growth
|
+5.98% | — | — | +12.47% |
|
Bajaj Finserv Overnight Fund
Direct Plan · Unclaimed less than 3 years IDCW Plan
|
+5.37% | — | — | +5.34% |
| Bajaj Finserv Nifty 1D Rate Liquid ETF - Growth | +4.85% | — | — | +4.26% |
|
Bajaj Finserv Gilt Fund
Direct Plan · IDCW
|
+4.75% | — | — | +4.64% |
|
Bajaj Finserv Equity Savings Fund
Direct Plan · IDCW
|
+4.48% | — | — | +4.53% |
|
Bajaj Finserv Banking and PSU Debt Fund
Direct Plan · IDCW
|
+3.94% | — | — | +7.04% |
About This Scheme
Investment Objective
The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies. However, there is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Equity and Equity Related Securities of pharma, healthcare and allied companies - 80% - 100%, Equities and Equity related securities of other than pharma, healthcare and allied companies - 0% - 20% Money market instruments*, other liquid instruments, Units of InvITs, Units of Gold ETFs and Silver ETFs and units of Liquid, Overnight and Money Market Mutual Fund - 0% - 20% *Money market instruments will include commercial papers,commercial bills, Triparty REPO, Reverse Repo and equivalent and any other like instruments as specified by SEBI and Reserve Bank of India from time to time.
Exit Load
Entry load – Nil Exit load – For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP) and Systematic Transfer Plan (STP), exit load will be as follows: • if units are redeemed / switched out within 3 months from the date of allotment: 1% of applicable NAV. • if units are redeemed/switched out after 3 months from the date of allotment, no exit load is payable. The Scheme will not levy exit load in case the timelines for rebalancing portfolio as stated in SEBI Master Circular for Mutual Funds dated June 27, 2024, is not complied with. The Trustee / AMC reserves the right to change the load structure any time in the future if they so deem fit on a prospective basis. The investor is requested to check the prevailing load structure of the scheme before investing.
Fund Managers
FM 1 - Mr. Bharat Hegde (Equity Portion) , FM 2 - Mr. Sorbh Gupta, (Equity Portion) , FM-3- Mr. Siddharth Chaudhary (Debt Portion)
FM 1 -Mr. Bharat Hegde and FM 2 - Mr. Sorbh Gupta, (Equity Portion) (Primary), FM 3 -Mr. Siddharth Chaudhary (Debt Portion) (Primary)
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.